Scientific Sessions 2025  /  Groundbreaking Trials in Cardiometabolic Therapeutics  /  The Next Era in Cardiometabolic Treatment
Logo

American Heart Association

  35
  0

Final ID:

The Next Era in Cardiometabolic Treatment

  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
    • Author Disclosures:
    Christie Ballantyne: DO have relevant financial relationships ; Researcher:merck:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Researcher:Novo Nordisk:Active (exists now) ; Consultant:Arrowhead:Active (exists now) ; Researcher:Arrowhead:Active (exists now) ; Consultant:Ionis:Active (exists now) ; Researcher:Ionis:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Researcher:Amgen:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Researcher:Eli Lilly:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Consultant:Merck:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, 11/08/2025 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
Olezarsen in Patients with Severe Hypertriglyceridemia: The CORE-TIMI 72a and CORE2-TIMI 72b Trials

Marston Nicholas, Zhang Shuanglu, Goodrich Erica, Murphy Sabina, Xia Shuting, Li Dan, Tsimikas Sotirios, Giugliano Robert, Sabatine Marc, Bergmark Brian, Alexander Vickie, Prohaska Thomas, Kang Yu Mi, Moura Filipe, Zimerman Andre, Waldman Elaine, Weinland Julia

Discussant

Lingvay Ildiko, Rosenson Robert

More abstracts from these authors:
Will apoCIII therapies tip the BALANCE towards targeting triglycerides?

Tsimikas Sotirios, Ballantyne Christie

Targets, Tools, and Tailored Therapy: What's New and What's Next in Lipid Management for Coronary Atherosclerosis

Ballantyne Christie

You have to be authorized to contact abstract author. Please, Login
Not Available